Nabriva Therapeutics
Latest round
- Series B
Last raised
- Apr 2015
Total raised
- $218M
Investors
- 10
About Nabriva Therapeutics
Founded in 2006 and headquartered in Vienna, Austria, Nabriva Therapeutics GmbH specializes in antibiotic development.00 mn. Nabriva has completed a total of 9 deals, with the most recent deal dated September 18, 2015.Nabriva Therapeutics focuses on the development of innovative therapeutic solutions for serious infections caused by antibiotic-resistant bacteria. Their core product offerings include a portfolio of antibiotics, with flagship products designed to treat acute bacterial skin and skin structure infections, as well as community-acquired bacterial pneumonia. These products utilize advanced compounds, such as lefamulin, which acts by inhibiting bacterial protein synthesis. Nabriva aims to address the critical need for effective treatments in an era where antibiotic resistance is a growing concern among healthcare providers and patients alike.90 mn in revenue for the year 2021. The company operates on a B2B model, selling its antibiotic products directly to healthcare institutions and pharmacies. The pricing structure of its products is influenced by market demand and the unique therapeutic value they offer. Nabriva's flagship product, lefamulin, significantly contributes to its revenue, with pricing strategies that reflect its formulation and the pressing need for effective treatment options against resistant infections.Nabriva Therapeutics is actively working on expanding its portfolio of innovative antibiotics, with plans to develop and launch new products addressing antibiotic-resistant infections in the coming years. The company aims to enter new markets in Asia and Latin America by 2024, driven by increasing demand for effective antibiotics.00 mn will be utilized to support research and development initiatives, enhance marketing strategies, and facilitate expansion into these emerging markets.
Who invested in Nabriva Therapeutics
10 investors across 4 rounds
See all investors in Nabriva Therapeutics
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Nabriva Therapeutics
Who invested in Nabriva Therapeutics?
Nabriva Therapeutics has 10 investors on record across 4 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Nabriva Therapeutics raised?
Nabriva Therapeutics has raised 4 venture rounds. Sign up free to see how much each round raised and the total.
When did Nabriva Therapeutics last raise money?
Nabriva Therapeutics's most recent round on record is a Series B, in Apr 2015.
What does Nabriva Therapeutics do?
Founded in 2006 and headquartered in Vienna, Austria, Nabriva Therapeutics GmbH specializes in antibiotic development.
Where is Nabriva Therapeutics headquartered?
Nabriva Therapeutics is headquartered in Vienna, Austria.
Which VCs invest in companies like Nabriva Therapeutics?
Among active investors with capital left to deploy, Index Ventures, Forbion, European Investment Bank and Generation Investment Management back pharmaceuticals companies at Nabriva Therapeutics's stage. Their profiles are linked below.
VCs backing pharmaceuticals startups at Series B
Raising like Nabriva Therapeutics? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.